Intravenous Iron Therapy for Children With Iron Deficiency Anemia.
Journal
Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928
Informations de publication
Date de publication:
01 01 2023
01 01 2023
Historique:
received:
30
06
2022
accepted:
11
08
2022
pubmed:
27
9
2022
medline:
7
1
2023
entrez:
26
9
2022
Statut:
ppublish
Résumé
Iron deficiency anemia in children is a public health problem. Although oral iron treatment is the first choice, common side effects and compliance problems can cause the treatment to be interrupted. This study retrospectively evaluated children treated with intravenous (IV) iron sucrose or ferric carboxymaltose (FCM) and compared the treatment processes and efficacy. The demographic characteristics and treatment details of the 44 children with iron deficiency anemia were retrospectively evaluated. Iron sucrose was administered to 25 patients and FCM was administered to 19 patients. The IV iron infusion was applied to 64% of the patients because of unresponsiveness to oral treatment, 25% of the patients because of compliance problems, and 11% of the patients because of severe anemia. IV iron therapy increased hemoglobin, mean corpuscular volume, mean corpuscular hemoglobin, red-cell distribution width, and serum ferritin levels and decreased platelet count. The mean number of infusions per patient in the FCM group was lower, and the total treatment time was shorter. In conclusion, IV iron sucrose or FCM can be used in children with nonadherence to oral therapy and severe anemia in addition to specific indications.
Identifiants
pubmed: 36161971
doi: 10.1097/MPH.0000000000002550
pii: 00043426-202301000-00022
doi:
Substances chimiques
Ferric Oxide, Saccharated
FZ7NYF5N8L
ferric carboxymaltose
6897GXD6OE
Ferric Compounds
0
Iron
E1UOL152H7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e56-e59Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Cappellini MD, Musallam KM, Taher AT. Iron deficiency anaemia revisited. J Intern Med. 2020;287:153–170.
Mattiello V, Schmugge M, Hengartner H, et al. SPOG Pediatric Hematology Working Group. Diagnosis and management of iron deficiency in children with or without anemia: consensus recommendations of the SPOG Pediatric Hematology Working Group. Eur J Pediatr. 2020;179:527–545.
Mantadakis E. Advances in pediatric intravenous iron therapy. Pediatr Blood Cancer. 2016;63:11–16.
Russo G, Guardabasso V, Romano F, et al. Monitoring oral iron therapy in children with iron deficiency anemia: an observational, prospective, multicenter study of AIEOP patients (Associazione Italiana Emato-Oncologia Pediatrica). Ann Hematol. 2020;99:413–420.
Stein RE, Plantz K, Maxwell EC, et al. Intravenous iron sucrose for treatment of iron deficiency anemia in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2018;66:e51–e55.
Papadopoulos M, Patel D, Korologou-Linden R, et al. Safety and efficacy of parenteral iron in children with inflammatory bowel disease. Br J Clin Pharmacol. 2018;84:694–699.
Gordon M, Sinopoulou V, Iheozor-Ejiofor Z, et al. Interventions for treating iron deficiency anaemia in inflammatory bowel disease. Cochrane Database Syst Rev. 2021;1:CD013529.
Cococcioni L, Pensabene L, El-Khouly S, et al. Ferric carboxymaltose treatment for iron deficiency anemia in children with inflammatory bowel disease: Efficacy and risk of hypophosphatemia. Dig Liver Dis. 2021;53:830–834.
Laass MW, Straub S, Chainey S, et al. Effectiveness and safety of ferric carboxymaltose treatment in children and adolescents with inflammatory bowel disease and other gastrointestinal diseases. BMC Gastroenterol. 2014;14:184.
Lanzkowsky P Lanzkowsky P, Lipton JM, Fish JD. Iron-deficiency anemia. Lanzkowsky’s Manual of Pediatric Hematology and Oncology, 6th ed. London: Elsevier; 2016:69–83.
Koleini N, Shapiro JS, Geier J, et al. Ironing out mechanisms of iron homeostasis and disorders of iron deficiency. J Clin Invest. 2021;131:e148671.
Toblli JE, Angerosa M. Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose. Drug Des Devel Ther. 2014;8:2475–2491.
Powers JM, Shamoun M, McCavit TL, et al. Intravenous ferric carboxymaltose in children with iron deficiency anemia who respond poorly to oral iron. J Pediatr. 2017;180:212–216.
DelRosso LM, Ferri R, Chen ML, et al. Clinical efficacy and safety of intravenous ferric carboxymaltose treatment of pediatric restless legs syndrome and periodic limb movement disorder. Sleep Med. 2021;87:114–118.
Tan MLN, Windscheif PM, Thornton G, et al. Retrospective review of effectiveness and safety of intravenous ferric carboxymaltose given to children with iron deficiency anaemia in one UK tertiary centre. Eur J Pediatr. 2017;176:1419–1423.
Panagopoulou P, Alexiadou S, Ntoumpara M, et al. Safety of ferric carboxymaltose in children: report of a case series from greece and review of the literature. Paediatr Drugs. 2022;24:137–146.
Kaneva K, Chow E, Rosenfield CG, et al. Intravenous iron sucrose for children with iron deficiency anemia. J Pediatr Hematol Oncol. 2017;39:e259–e262.
Sabe R, Vatsayan A, Mahran A, et al. Safety and efficacy of intravenous iron sucrose for iron-deficiency anemia in children and adolescents with inflammatory bowel disease. Glob Pediatr Health. 2019;6:2333794X19870981.
Mantadakis E, Tsouvala E, Xanthopoulou V, et al. Intravenous iron sucrose for children with iron deficiency anemia: a single institution study. World J Pediatr. 2016;12:109–113.
Akin M, Atay E, Oztekin O, et al. Responsiveness to parenteral iron therapy in children with oral iron-refractory iron-deficiency anemia. Pediatr Hematol Oncol. 2014;31:57–61.